Synthetic Biologics

OverviewSuggest Edit

Synthetic Biologics is a late-stage clinical company developing therapeutics designed to preserve the microbiome. The Company is developing an oral enzyme for the prevention of C. difficile infections, and a series of monoclonal antibody therapies for the treatment of Pertussis and Acinetobacter infections. In addition, it is developing a drug candidate for the treatment of relapsing-remitting multiple sclerosis and cognitive dysfunction in multiple sclerosis.

TypePublic
Founded2001
HQRockville, US
Websitesyntheticbiologics.com

Latest Updates

Employees (est.) (Feb 2020)11(-15%)
Revenue (FY, 2011)$0
Share Price (Oct 2020)$0.3
Cybersecurity ratingAMore

Key People/Management at Synthetic Biologics

Steven Shallcross

Steven Shallcross

Chief Executive Officer, Chief Financial Officer, Treasurer and Secretary, Director
Jeffrey J. Kraws

Jeffrey J. Kraws

Chairman
Scott L. Tarriff

Scott L. Tarriff

Director
Michael Kaleko

Michael Kaleko

Senior Vice President, Research & Development
Jeffrey Wolf

Jeffrey Wolf

Director
Show more

Synthetic Biologics Office Locations

Synthetic Biologics has an office in Rockville
Rockville, US (HQ)
9605 Medical Center Dr #270
Show all (1)

Synthetic Biologics Financials and Metrics

Synthetic Biologics Revenue

USD

Net income (Q2, 2020)

(2.9m)

EBIT (Q2, 2020)

(2.9m)

Market capitalization (16-Oct-2020)

6.5m

Closing stock price (16-Oct-2020)

0.3

Cash (30-Jun-2020)

8.1m

EV

(979.5k)
Synthetic Biologics's current market capitalization is $6.5 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

General and administrative expense

2.6m5.0m5.8m6.0m8.1m10.1m7.5m5.7m4.6m

R&D expense

3.3m12.3m6.5m14.5m32.9m29.1m18.8m11.8m11.1m

Operating expense total

5.9m17.3m12.3m20.5m41.0m39.3m26.3m17.6m15.7m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

355.6k293.4k

General and administrative expense

694.3k681.8k1.5m1.2m1.1m1.1m1.3m1.9m1.1m1.8m1.2m1.7m2.2m1.6m2.4m2.1m2.1m2.1m1.6m1.7m1.6m1.4m1.5m1.2m1.0m1.1m1.4m1.3m

R&D expense

279.6k289.0k386.0k547.0k763.0k1.1m1.2m1.5m2.7m2.8m3.7m6.5m7.5m10.0m8.2m7.2m7.1m6.1m4.8m4.1m3.4m3.6m2.8m2.4m2.6m4.1m1.6m1.6m

Operating expense total

973.9k970.8k1.9m1.7m1.8m2.2m2.5m3.4m3.8m4.7m4.9m8.2m9.7m11.7m10.6m9.3m9.2m8.1m6.5m5.8m5.0m5.0m4.3m3.6m3.6m5.2m3.0m2.9m
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

6.7m10.0m14.6m17.5m20.8m19.1m17.1m28.9m15.0m

Accounts Receivable

405.0k

Prepaid Expenses

16.0k2.5m1.6m1.5m9.5m827.0k593.0k1.4m

Inventories

2.5m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

8.4m4.6m6.8m5.9m4.5m7.6m6.9m5.1m11.2m7.8m3.3m12.0m4.8m31.8m15.1m10.0m4.5m13.5m13.4m21.1m11.0m7.1m9.5m24.7m21.7m18.7m10.1m8.1m

Accounts Receivable

444.7k494.9k440.0k245.0k122.0k

Prepaid Expenses

75.5k123.8k83.0k94.0k151.0k2.2m1.9m1.6m1.3m1.4m1.4m1.6m7.0m10.3m7.1m5.8m3.1m3.4m1.5m1.3m606.0k535.0k559.0k860.0k1.3m1.2m1.1m897.0k

Current Assets

8.9m8.1m7.3m6.3m4.9m11.5m9.5m6.8m12.5m9.2m4.7m13.6m11.7m42.1m22.2m15.8m7.6m16.8m14.9m22.3m11.6m7.7m10.1m25.6m23.0m19.8m11.2m9.0m
USDQ2, 2011

Financial Leverage

1 x
Show all financial metrics

Synthetic Biologics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

99/100

SecurityScorecard logo

Synthetic Biologics Online and Social Media Presence

Embed Graph

Synthetic Biologics News and Updates

Synthetic Biologics Reports on NYSE American Noncompliance Notice and Compliance Plan

ROCKVILLE, Md., Nov. 27, 2019 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, today announced it...

Synthetic Biologics Reports Second Quarter 2019 Operational Highlights and Financial Results

ROCKVILLE, Md., Aug. 8, 2019 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, today provided an operational update and reported financial...

Synthetic Biologics to Report 2018 Year End Operational Highlights and Financial Results on February 27, 2019

ROCKVILLE, Md., Feb. 19, 2019 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, intends to report operational highlights and financial...

Synthetic Biologics Announces Positive Outcome of End-of-Phase 2 Meeting with FDA on SYN-004 (ribaxamase) Development

ROCKVILLE, Md., Nov. 21, 2018 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, today announced that it has successfully completed an...

Synthetic Biologics Reports Third Quarter 2018 Operational Highlights and Financial Results

ROCKVILLE, Md., Nov. 8, 2018 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, today provided an operational update and reported financial ...

Synthetic Biologics to Report Third Quarter 2018 Operational Highlights and Financial Results on November 8, 2018

ROCKVILLE, Md., Oct. 30, 2018 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today that the Company intends to release its...
Show more

Synthetic Biologics Frequently Asked Questions

  • When was Synthetic Biologics founded?

    Synthetic Biologics was founded in 2001.

  • Who are Synthetic Biologics key executives?

    Synthetic Biologics's key executives are Steven Shallcross, Jeffrey J. Kraws and Scott L. Tarriff.

  • How many employees does Synthetic Biologics have?

    Synthetic Biologics has 11 employees.

  • Who are Synthetic Biologics competitors?

    Competitors of Synthetic Biologics include Biogen, MyoKardia and Reata Pharmaceuticals.

  • Where is Synthetic Biologics headquarters?

    Synthetic Biologics headquarters is located at 9605 Medical Center Dr #270, Rockville.

  • Where are Synthetic Biologics offices?

    Synthetic Biologics has an office in Rockville.

  • How many offices does Synthetic Biologics have?

    Synthetic Biologics has 1 office.